Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 3:09 AM
Ignite Modification Date:
2025-12-25 @ 3:09 AM
NCT ID:
NCT02351505
Brief Summary:
This phase II trial studies how well selinexor work in treating patients with small-cell lung cancer that has returned after a period of improvement. One specific way cancer cells continue to grow is by getting rid of certain proteins called "tumor suppressor proteins: that would normally cause cancer cells to die. Selinexor works by trapping "tumor suppressing proteins" within the cell and may cause the cancer cells to die or stop growing.
Detailed Description:
PRIMARY OBJECTIVES:
I. To evaluate the efficacy of single agent selinexor as measured by progression free survival (PFS) in patients with relapsed chemotherapy-sensitive small cell lung cancer.
SECONDARY OBJECTIVES:
I. To evaluate the objective tumor response rate and disease control rate as determined by radiographic response.
II. To evaluate the overall survival (OS) in patients with relapsed small cell lung cancer.
III. To evaluate safety and tolerability of single agent selinexor in these patient populations.
IV. Comparison between each patient's time to progression (TTP) on selinexor with the TTP of his/her previous therapy(ies).
V. To evaluate correlative endpoints including tumor biopsy and analysis of secreted factors, leukocyte ribonucleic acid (RNA) analysis.
TERTIARY OBJECTIVES:
I. Analysis of secreted factors (nerve growth factor \[NGF\], brain-derived neurotrophic factor \[BDNF\]).
II. Tumor biopsy (baseline and cycle 2).
OUTLINE:
Patients receive selinexor orally (PO) twice weekly. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up monthly for 3 months, every 3 months for 1 year, and then every 6 months thereafter.
Study:
NCT02351505
Study Brief:
Protocol Section:
NCT02351505